Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

the clorox co. - CLX

CLX

Close Chg Chg %
164.33 -1.26 -0.77%

Closed Market

163.07

-1.26 (0.77%)

Volume: 766.08K

Last Updated:

Dec 23, 2024, 3:59 PM EDT

Trade Now

Company Overview: the clorox co. - CLX

CLX Key Data

Open

$164.13

 Day Range

160.89 - 164.13

52 Week Range

127.60 - 171.37

 Market Cap

$20.35B

Shares Outstanding

123.78M

 Public Float

123.40M

Beta

0.41

 Rev. Per Employee

N/A

P/E Ratio

57.55

 EPS

$2.88

Yield

294.33%

 Dividend

$1.22

EX-DIVIDEND DATE

Jan 29, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.22M

  

CLX Performance

1 Week
 
 -0.82%
 
1 Month
 
 -3.67%
 
3 Months
 
 -0.20%
 
1 Year
 
 14.97%
 
5 Years
 
 6.23%
 

CLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 24
Full Ratings ➔

About the clorox co. - CLX

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

CLX At a Glance

The Clorox Co.
1221 Broadway
Oakland, California 94612-1888
Phone 1-510-271-7000 Revenue 7.09B
Industry Household/Personal Care Net Income 280.00M
Sector Consumer Non-Durables Employees 8,000
Fiscal Year-end 06 / 2025
View SEC Filings

CLX Valuation

P/E Current 57.555
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 60.829
Price to Sales Ratio 2.401
Price to Book Ratio 51.676
Price to Cash Flow Ratio 24.507
Enterprise Value to EBITDA 17.316
Enterprise Value to Sales 2.81
Total Debt to Enterprise Value 0.147

CLX Efficiency

Revenue/Employee 886,625.00
Income Per Employee 35,000.00
Receivables Turnover 10.206
Total Asset Turnover 1.213

CLX Liquidity

Current Ratio 1.03
Quick Ratio 0.626
Cash Ratio 0.128

CLX Profitability

Gross Margin 42.648
Operating Margin 12.914
Pretax Margin 5.611
Net Margin 3.948
Return on Assets 4.788
Return on Equity 102.19
Return on Total Capital 8.576
Return on Invested Capital 9.044

CLX Capital Structure

Total Debt to Total Equity 895.427
Total Debt to Total Capital 89.954
Total Debt to Total Assets 51.069
Long-Term Debt to Equity 864.634
Long-Term Debt to Total Capital 86.861
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for The Clorox Co. - CLX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
7.34B 7.11B 7.39B 7.09B
Sales Growth
+9.22% -3.19% +3.97% -4.01%
Cost of Goods Sold (COGS) incl D&A
4.16B 4.62B 4.52B 4.07B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
210.00M 224.00M 236.00M 235.00M
Depreciation
179.00M 193.00M 206.00M 206.00M
Amortization of Intangibles
31.00M 31.00M 30.00M 29.00M
COGS Growth
+13.44% +10.96% -2.12% -9.96%
Gross Income
3.18B 2.49B 2.87B 3.02B
Gross Income Growth
+4.16% -21.69% +15.25% +5.36%
Gross Profit Margin
+43.33% +35.05% +38.86% +42.65%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.94B 1.79B 2.04B 2.11B
Research & Development
149.00M 132.00M 139.00M 126.00M
Other SG&A
1.79B 1.66B 1.91B 1.98B
SGA Growth
+8.61% -7.62% +13.87% +3.18%
Other Operating Expense
- - - -
-
Unusual Expense
258.00M (14.00M) 505.00M 16.00M
EBIT after Unusual Expense
980.00M 710.00M 322.00M 900.00M
Non Operating Income/Expense
13.00M (6.00M) 19.00M (399.00M)
Non-Operating Interest Income
5.00M 5.00M 16.00M 23.00M
Equity in Earnings of Affiliates
5.00M 6.00M 4.00M 5.00M
Interest Expense
93.00M 97.00M 103.00M 103.00M
Interest Expense Growth
- - +4.30% +6.19%
-
Gross Interest Expense
93.00M 97.00M 103.00M 103.00M
Interest Capitalized
- - - -
-
Pretax Income
900.00M 607.00M 238.00M 398.00M
Pretax Income Growth
-24.05% -32.56% -60.79% +67.23%
Pretax Margin
+12.26% +8.54% +3.22% +5.61%
Income Tax
181.00M 136.00M 77.00M 106.00M
Income Tax - Current - Domestic
172.00M 88.00M 186.00M 150.00M
Income Tax - Current - Foreign
41.00M 43.00M 40.00M 56.00M
Income Tax - Deferred - Domestic
(35.00M) 4.00M (148.00M) (104.00M)
Income Tax - Deferred - Foreign
3.00M 1.00M (1.00M) 4.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
5.00M 6.00M 4.00M 5.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
719.00M 471.00M 161.00M 292.00M
Minority Interest Expense
9.00M 9.00M 12.00M 12.00M
Net Income
710.00M 462.00M 149.00M 280.00M
Net Income Growth
-24.39% -34.93% -67.75% +87.92%
Net Margin Growth
+9.67% +6.50% +2.02% +3.95%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
710.00M 462.00M 149.00M 280.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
710.00M 462.00M 149.00M 280.00M
EPS (Basic)
5.6542 3.7526 1.2056 2.2549
EPS (Basic) Growth
-24.23% -33.63% -67.87% +87.04%
Basic Shares Outstanding
125.57M 123.11M 123.59M 124.17M
EPS (Diluted)
5.5774 3.7286 1.1999 2.2435
EPS (Diluted) Growth
-24.17% -33.15% -67.82% +86.97%
Diluted Shares Outstanding
127.30M 123.91M 124.18M 124.80M
EBITDA
1.45B 920.00M 1.06B 1.15B
EBITDA Growth
+0.28% -36.46% +15.54% +8.28%
EBITDA Margin
+19.72% +12.94% +14.39% +16.23%

Snapshot

Average Recommendation HOLD Average Target Price 163.00
Number of Ratings 24 Current Quarters Estimate 1.394
FY Report Date 12 / 2024 Current Year's Estimate 6.85
Last Quarter’s Earnings 1.86 Median PE on CY Estimate N/A
Year Ago Earnings 6.17 Next Fiscal Year Estimate 7.257
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 17 19 20
Mean Estimate 1.39 1.63 6.85 7.26
High Estimates 1.57 1.78 7.03 7.67
Low Estimate 1.24 1.43 6.68 6.61
Coefficient of Variance 6.06 5.33 1.10 3.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 3
HOLD 17 16 14
UNDERWEIGHT 0 0 0
SELL 5 5 6
MEAN Hold Hold Hold

Insider Actions for The Clorox Co. - CLX

Date Name Shares Transaction Value
Jul 25, 2024 Nina Barton EVP-Group Pres-Care & Conn 18,041 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $133.03 per share 2,399,994.23
Jul 18, 2024 Chris T Hyder Group President - Health & Hyg 13,770 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $134.15 per share 1,847,245.50
Jul 3, 2024 Russell John Weiner Director 12,759 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Stephanie Plaines Director 3,292 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Stephanie Plaines Director 3,099 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Amy L. Banse Director 7,970 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Amy L. Banse Director 363 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $136.47 per share 49,538.61
Jul 3, 2024 Paul G. Parker Director 3,256 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Paul G. Parker Director 898 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $136.47 per share 122,550.06
Jul 3, 2024 Spencer Charles Fleischer Director 15,772 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Russell John Weiner Director 12,567 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Kathryn A. Tesija Director 6,552 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Kathryn A. Tesija Director 6,359 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Matthew J. Shattock Director 13,595 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Matthew J. Shattock Director 13,220 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Christopher Judson Williams Director 16,999 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Christopher Judson Williams Director 450 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $136.47 per share 61,411.50
Jul 3, 2024 Spencer Charles Fleischer Director 16,001 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

The Clorox Co. in the News